Protected against oral oral dosage form containing (1r, 2r) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol The present invention relates to an oral protected pharmaceutical form abuse, with controlled release of (1r-2r) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol for single daily administration, characterized in that it comprises the active ingredient and / or a or a number of pharmaceutically acceptable compounds (a) thereof, at least one synthetic and / or natural polymer (c) sustained release adjuvants, optionally other physiologically compatible adjuvants (b) and optionally a wax (d) having the pharmaceutical form, in each case, a breaking strength of at least 500 n, preferably at least 750 n. the pharmaceutical form includes at least one of the following abuse-preventing components (a) to (f): (a) at least one substance that irritates the nasal and / or pharyngeal cavity, (b) at least one agent which increases the viscosity, (c) at least one antagonist for the active substance with potential for abuse, (d) at least one emetic, (e) at least one colorant as a deterrent, (f) at least one bitter substance.forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol a presente invenção refere-se a uma forma farmacêutica oral, protegida frente ao abuso, com liberação controlada de (1r-2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol para uma administração única diária, caracterizada pelo fato de que compreende o principio ativo e/ou um ou vários dos seus compostos (a) farmaceuticamente aceitáveis, pelo menos um polímero (c) sintético e/ou natural, adjuvantes de liberação sustentada, opcionalmente outros adjuvantes (b) fisiologicamente compatíveis e opcionalmente uma cera (d), tendo a forma farmacêutica, em cada caso, uma resistência ao rompimento de pelo menos 500 n, preferivelmente de pelo menos 750n. a forma farmacêutica inclui pelo menos um dos seguintes componentes de (a) a (f) que evitam
